Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial.
Level 2 - randomized trial
Individual randomized, double-blind, placebo-controlled trial.
PubMed 26519439 · doi:10.3233/JAD-150538
What was done
A randomized, double-blind, placebo-controlled, parallel-design trial evaluated the efficacy of MMFS-01 in 44 older adults (aged 50–70) with cognitive impairment. Participants received either MMFS-01 (n = 23) or placebo (n = 21) for 12 weeks. Outcomes evaluated included overall cognitive ability (composite score across four major domains), cognitive fluctuation, executive function, sleep quality, and emotion/anxiety.
What was found
MMFS-01 treatment significantly improved overall cognitive ability relative to placebo (p = 0.003; Cohen's d = 0.91) and reduced cognitive fluctuation. Impaired executive function was reported as nearly restored relative to normative data. Effects on sleep quality and anxiety could not be determined due to strong placebo effects. Specific numerical scores for cognitive subdomains and safety data were not reported in the abstract.
Why it matters
This study provides preliminary clinical evidence that MMFS-01, proposed as a synapse density enhancer, may improve executive function and overall cognitive scores in older adults with cognitive deficits over 12 weeks.
Limits
The total sample size was very small (n = 44 across both arms), increasing the risk of imprecision. The trial duration was limited to 12 weeks. The abstract does not report baseline values, absolute score changes, or safety/adverse event findings, and high placebo response precluded evaluation of sleep and anxiety outcomes.